Company AroCell AB

Equities

AROC

SE0003883990

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for AroCell AB

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 08:26:08 14/05/2024 pm IST			5-day change	1st Jan Change
0.418 ^SEK	+1.21%		-3.91%	-4.35%

03/05	AroCell AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
18/04	Swedish Diagnostics Company AroCell Secures US Patent	MT

AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.

Number of employees: 22

SEK in Million	2020	Weight	2021	Weight	Delta
Research and Development in Cell Biology and Medicine 100.0 %	0	100.0 %	12	100.0 %	+14,180.95%

SEK in Million	2020	Weight	2021	Weight	Delta
Sweden 100.0 %	0	100.0 %	12	100.0 %	+14,180.95%

Managers	Title	Age	Since
Anders Hultman CEO	Chief Executive Officer	50	01/18/01
Lars Jakobsson DFI	Director of Finance/CFO	67	-
Gustav Sten COO	Chief Operating Officer	-	01/19/01
Gunnar Steineck CTO	Chief Tech/Sci/R&D Officer	-	01/17/01
Kiran Kumar Jagarlamudi CTO	Chief Tech/Sci/R&D Officer	-	01/15/01
Alona Nyberg IRC	Investor Relations Contact	-	01/19/01
Gunnar Wahlberg SAM	Sales & Marketing	54	01/21/01
Tina Yang PRN	Corporate Officer/Principal	-	01/17/01
Peter Lowendahl LAW	General Counsel	-	01/19/01
Filip Fogdestam PRN	Corporate Officer/Principal	-	01/14/01

Members of the board	Title	Age	Since
Johan Erik Häggblad CHM	Chairman	65	01/22/01
Charlotta Ljungqvist BRD	Director/Board Member	63	01/21/01
Clas Runnberg BRD	Director/Board Member	72	01/23/01
Gunnar Steineck CTO	Chief Tech/Sci/R&D Officer	-	01/17/01
Max Pihlqvist BRD	Director/Board Member	37	01/22/01
Eva Nordström BRD	Director/Board Member	54	01/20/01
Agneta Tufvesson Alm BRD	Director/Board Member	-	01/22/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	230,361,066	102,183,486 ( 44.36 %)	0	44.36 %

Name	Equities	%	Valuation
Arvernus Capital AG 0.1912 %	440,492	0.1912 %	15 893 kr

AroCell AB

Karlsbodavägen 39

168 67, Bromma Stockholm

+46 87 99 67 50

http://www.arocell.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
AROCELL AB	-4.35%	8.77M
MODERNA, INC.	+29.03%	48.16B
IQVIA HOLDINGS INC.	-0.10%	41.73B
LONZA GROUP AG	+43.45%	41.03B
CELLTRION, INC.	-5.26%	28.77B
ICON PUBLIC LIMITED COMPANY	+11.48%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.96B
BIO-TECHNE CORPORATION	+9.06%	12.92B
MEDPACE HOLDINGS, INC.	+30.01%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.77B

Other Biotechnology & Medical Research